Department of Radiation Oncology, The Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead Sydney, NSW, 2145, Australia.
Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW, Australia.
Sci Rep. 2021 Mar 15;11(1):5939. doi: 10.1038/s41598-021-85131-7.
Treatment-related toxicity is an important component in non-small cell lung cancer (NSCLC) management decision-making. Our aim was to evaluate and compare the toxicity rates of curative and palliative radiotherapy with and without chemotherapy. This meta-analysis provides better quantitative estimates of the toxicities compared to individual trials. A systematic review of randomised trials with > 50 unresectable NSCLC patients, treated with curative or palliative conventional radiotherapy (RT) with or without chemotherapy. Data was extracted for oesophagitis, pneumonitis, cardiac events, pulmonary fibrosis, myelopathy and neutropenia by any grade, grade ≥ 3 and treatment-related deaths. Mantel-Haenszel fixed-effect method was used to obtain pooled risk ratio. Forty-nine trials with 8609 evaluable patients were included. There was significantly less grade ≥ 3 acute oesophagitis (6.4 vs 22.2%, p < 0.0001) and any grade oesophagitis (70.4 vs 79.0%, p = 0.04) for sequential CRT compared to concurrent CRT, with no difference in pneumonitis (grade ≥ 3 or any grade), neutropenia (grade ≥ 3), cardiac events (grade ≥ 3) or treatment-related deaths. Although the rate of toxicity increased with intensification of treatment with RT, the only significant difference between treatment regimens was the rate of oesophagitis between the use of concurrent and sequential CRT. This can aid clinicians in radiotherapy decision making for NSCLC.
与单纯放疗相比,放化疗联合治疗非小细胞肺癌(NSCLC)可显著提高疗效,但毒性反应也相应增加。本研究旨在评估并比较根治性和姑息性放疗联合或不联合化疗的毒性反应发生率。与传统的个体化临床试验相比,荟萃分析能够提供更好的定量毒性估计。
系统检索了 50 例以上不能手术的 NSCLC 患者接受根治性或姑息性常规放疗(RT)联合或不联合化疗的随机临床试验。提取食管炎、放射性肺炎、心脏事件、肺纤维化、脊髓病和中性粒细胞减少症的任何级别、≥3 级和治疗相关死亡的发生率。采用 Mantel-Haenszel 固定效应法计算合并风险比(RR)。
共纳入 49 项试验,8609 例患者可评估。序贯 CRT 较同期 CRT 治疗的 3 级或更高级别的急性食管炎(6.4% vs 22.2%,p<0.0001)和任何级别的食管炎(70.4% vs 79.0%,p=0.04)发生率显著降低,但放射性肺炎(≥3 级或任何级别)、中性粒细胞减少症(≥3 级)、心脏事件(≥3 级)或治疗相关死亡无差异。尽管随着 RT 治疗强度的增加,毒性反应发生率增加,但同期和序贯 CRT 之间的唯一显著差异是食管炎的发生率。这有助于临床医生在 NSCLC 的放射治疗决策中做出选择。